Expansion of CpG Methylation in the SFRP2 Promoter Region during Colorectal Tumorigenesis by Takeda, Masanori et al.
Expansion of CpG Methylation in the SFRP2 Promoter Region 
during Colorectal Tumorigenesis
Masanori Takedaa,  Takeshi Nagasakaa＊,  Sun Dong-Shenga,  Hiroyuki Nishieb,   
Tetsuhiro Okaa,  Eiji Yamadaa,  Yoshiko Moria,  Kunitoshi Shigeyasua,   
Tatsuya Morikawaa,  Satoshi Mizobuchib,  and Toshiyoshi Fujiwaraa
Departments of aGastroenterological Surgery and Surgical Oncology,  and bAnesthesiology and Resuscitology,   
Okayama University Graduate School of Medicine,  Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan
Secreted frizzled-related protein 2,  (SFRP2) is a Wnt inhibitor whose promoter CpGs were recently 
found to be methylated at high frequency in colorectal cancers (CRCs).  We hypothesized that the pat-
tern of SFRP2 methylation may diﬀer throughout the promoter during progressive tumorigenesis.  
Using combined bisulﬁte restriction analysis (COBRA),  two methylation-sensitive regions (Regions A 
and B) of the SFRP2 promoter were investigated in 569 specimens of colorectal tissue: 222 CRCs,  103 
adenomatous polyps (APs),  208 normal colonic mucosa from CRC patients (N-Cs),  and 36 normal 
colonic mucosa from subjects with no evidence of colorectal neoplasia at colonoscopy (N-Ns).  
Extensive (including both Regions A and B) and partial (either Region A or B) SFRP2 methylation 
levels were found in 61.7ｵ and 24.8ｵ of CRCs,  8.7ｵ and 37.9ｵ of APs,  3.9ｵ and 39.9ｵ of N-Cs,  and 
0ｵ and 30.6ｵ of N-Ns,  respectively.  Extensive methylation of the SFRP2 promoter was present pri-
marily in CRCs,  while partial methylation was common in APs.  Whereas APs with the KRAS mutant 
showed no correlation to any pattern of SFRP2 methylation,  extensive methylation of the SFRP2 
promoter was signiﬁcantly associated with KRAS mutant CRCs (p＜ .0001),  suggesting that genetic 
alteration in the RAS-RAF pathway might precede the spread of CpG methylation through the SFRP2 
promoter,  which is observed in over 60ｵ of advanced colorectal tumors.
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berrant WNT pathway signaling is an early 
progression event in approximately 90ｵ of 
CRCs and occurs through mutations mainly of APC 
and,  less often,  of CTNNB1 (encoding beta-catenin).  
These mutations allow ligand-independent WNT signal-
ing that culminates in abnormal accumulation of free 
beta-catenin in the nucleus [1-3].  Secreted frizzled-
related proteins (SFRPs) possess a domain similar to 
one in the WNT-receptor frizzled proteins and can 
inhibit WNT receptor binding to downregulate path-
way signaling during development [4].  Recently,  gene 
silencing of SFRPs,  which consist of 5 members 
(SFRP1-5),  by the hypermethylation of their pro-
moter was identiﬁed in CRCs and other malignancies 
[5-10].  Especially,  SFRP2 methylation was detected 
with a high frequency of over 60ｵ of CRCs,  includ-
ing Lynch syndrome,  which suggests that SFRP2 
methylation might potentially be useful as a promising 
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sensitive screening marker for the stool-based detec-
tion of CRCs and premalignant lesions,  as our previ-
ous study demonstrated [11-13].  Additionally,  we 
also demonstrated that methylation in the SFRP2 
promoter was more likely to be found in CRCs with 
the KRAS mutant [8].  Although the detailed mecha-
nisms underlying hypermethylation are still unclear,  
we have recently described the gradual expansion of 
methylated CpG residues in the MGMT promoter in a 
normal-adenoma-carcinoma sequence [14].  Herein we 
show that SFRP2 methylation also expands methylated 
CpG residues throughout the promoter in a stepwise 
manner through the adenoma-cancer multistep cascade.
Materials and Methods
　 Tissue samples. Tissue specimens from 222 
CRCs and 208 adjacent normal colorectal mucosa 
(“normal from cancer patients”,  or N-C) were obtained 
from patients with colorectal cancer who had under-
gone curative surgery at Okayama University Hospital,  
Okayama,  Japan,  between 1994 and 2007.  We 
excluded CRCs that occurred in patients with a family 
history of CRC.  A total of 103 APs and colonic 
biopsy specimens from 36 subjects with no evidence of 
colorectal neoplasia at colonoscopy (“normal from non-
neoplastic colons” or N-N) were obtained from subjects 
who had received a colonoscopy at Chikuba Hospital 
and Okayama University Hospital,  Okayama,  Japan,  
from 2002 to 2007,  as described previously [8].  The 
tumor/node/metastasis (TNM) classiﬁcation system 
was used for cancer staging [14].  APs were divided 
into two subsets: advanced polyps (i.e.,  polyps with 
high-grade dysplasia,  villous architecture,  and tubular 
adenomasｧ1cm in diameter: 82 specimens),  and 
minor polyps (simple tubular adenomas＜1cm in diam-
eter: 21 specimens).  Institutional review board 
approval was granted,  and informed consent was 
obtained from all subjects to use their tissues.
　 DNA isolation and bisulphite modiﬁcation.
DNA was extracted from CRC,  N-C,  and N-N tissues 
by standard procedures described previously [15].  
All DNA from APs was extracted from formalin-ﬁxed,  
paraﬃn-embedded archival materials.  For each AP,  
DNA was extracted using a TaKaRa DEXPAT kit 
(Takara Bio Inc.,  Otsu,  Japan).  Then,  200 to 1, 000 
ng of genomic DNA was subjected to sodium bisulﬁte 
modiﬁcation.  Bisulﬁte modiﬁcation was carried out 
using a CpGenome DNA Modiﬁcation Kit (Intergen 
Co.,  Purchase,  NY,  USA).
　 Combined bisulfite restriction analysis 
(COBRA) assays for SFRP2 methylation. We 
designed the COBRA to examine both ʻRegion Aʼ and 
ʻRegion Bʼ of the SFRP2 promoter (Fig.  1A).  Primer 
sequences for “Region A” and “Region B” COBRA for 
the SFRP2 promoter region were: (a) Region A-F 
(5ʼ-GTYGGAGTTTTTYGGAGTTG-3ʼ) and Region 
A-R (5ʼ-AACCCRCTCTCTTCRCTAAATAC-3ʼ), and 
(b) Region B-F (5ʼ-GGTTGTTAGTTTTTYGGGGT 
TT-3ʼ) and Region B-R (5ʼ-CAACIAACCAAAACCC 
TACAACAT-3ʼ),  generating fragment lengths of 139 
and 153 bp,  respectively.  COBRA was carried out in 
a 25µl PCR mixture containing 12.5µl of HotStarTaq 
Master Mix kit (Qiagen).  The PCR products derived 
from Region A were digested with BssHII (New 
England Biolabs,  Ipswich,  MA,  USA) at 50℃ for 
16h,  and those from Region B were digested with 
HhaI (New England Biolabs) at 37℃ for 16h.  The 
digested DNA was separated on 3ｵ agarose gels in 1x 
TAE buﬀer and stained with ethidium bromide.  We 
used a Gel Logic 200 Imaging System (Eastman 
Kodak Co.,  Rochester,  NY,  USA) to perform densi-
tometric analyses on all gels.  Band intensities were 
quantiﬁed using Kodak 1D analysis software (Eastman 
Kodak Co.).  The methylation levels (ratios of methy-
lated to unmethylated DNA) were determined from the 
relative intensities of cut and uncut PCR products to 
quantitate methylation.
　 Microsatellite instability (MSI) testing and 
BRAF/KRAS mutation analysis. MSI testing 
and BRAF V600E mutation/KRAS mutations at codons 
12 and 13 were determined by methods described 
previously [8,  11].
　 Statistical analysis. The methylation statuses 
of both regions in the SFRP2 promoter as determined 
by COBRA were analyzed as categorical variables 
(positive: methylation levelｧ1ｵ,  negative: methyla-
tion level＜1ｵ by using Kodak 1D analysis software).  
Methylation levels of specimens classiﬁed as methyla-
tion-positive were analyzed as a continuous variable,  
and these data were expressed on a log scale by calcu-
lating Spearmanʼs rank correlation coeﬃcients (p).  A 
correlation between subjects was considered strong 
when |p|ｧ0.7,  but the correlation was weaker when 
|p| was between 0.5-0.7.  Diﬀerences in frequency 
were evaluated by the χ2-test.  All reported p values 
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were two-sided,  and a p value＜0.05 was considered 
statistically signiﬁcant.
Results
　 Tissue characteristics. To clarify the fea-
tures of SFRP2 methylation through colorectal tum-
origenesis,  we collected and analyzed colorectal tis-
sues obtained from 36 N-Ns,  208 N-Cs,  103 APs,  
and 222 CRCs.  Table 1 shows the clinical informa-
tion on 569 colorectal tissues.  There were no diﬀer-
ences in age or gender among all colorectal subsets,  
or in tumor location between APs and CRCs in the 
study cohort.
　 Methylation proﬁles in the SFRP2 promoter.
COBRA for SFRP2 was designed to examine the 
methylation status in 2 regions of the SFRP2 pro-
moter (Regions A and B) as shown in Fig.  1A.  By 
analogy,  we divided the human SFRP2 promoter into 
these 2 regions.  We chose Region A based on 
sequence homology to the mouse sfrp2 promoter 
sequence,  which suggested that this region might be a 
binding site for the transcriptional factor pax2 [16].  
We chose Region B based on previous studies in which 
we showed that this promoter region was aberrantly 
methylated at high frequency in CRC specimens [8].  
When we consider methylation-positive as methylation 
levelｧ1ｵ by COBRA,  SFRP2 methylation (partial 
or extensive) was observed in 30.6ｵ of N-Ns,  43.8ｵ 
of N-Cs,  46.6ｵ of APs,  and 87.6ｵ of CRCs (Table 
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Table 1　 Clinical features of colorectal specimens
Variable
Normal colonic mucosa 
without Neoplasia
(N-N; n＝36)
Normal colonic mucosa 
from CRC patients
(N-C; n＝208)
Adenomatous polyp
(AP; n＝103)
Colorectal cancer
(CRC; n＝222) p-value
Age ｧ65 50.0 (18) 51.0 (106) 51.5 (53) 52.7 (117) 0.98
＜65 50.0 (18) 49.0 (102) 48.5 (50) 47.3 (105)
Gender Female 44.4 (16) 35.6 ( 74 ) 26.2 (27) 36.4 ( 79 ) 0.16
Male 55.6 (20) 64.4 (134) 73.8 (76) 63.4 (138)
Location Proximal － － 32.0 (33) 30.7 ( 63 ) 0.82
Distal － － 68.0 (70) 69.3 (142)
All p-values are analyzed by χ2-test.
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Fig. 1　 (A) Schematic representation of SFRP2 gene promoter regions analyzed by combined bisulﬁte restriction analysis (COBRA).  
Black squares represent the coding exon 1 region; arrows on the squares indicate transcriptional start sites.  Vertical lines indicate CpG 
sites.  White diamonds represent the restriction sites for BssHII,  and gray diamonds represent restriction sites for HhaI.  Thick horizontal 
lines depict the locations of COBRA products,  (B) Representative results of COBRA in the 2 regions (Regions A and B) of SFRP2.  Arrows 
indicate methylated alleles.  Mc denotes methylated control.  SM denotes a size marker.
2).  However,  extensive (including both Regions A and 
B) SFRP2 methylation was observed in only 0ｵ of 
N-Ns,  3.9ｵ of N-Cs,  8.7ｵ of APs,  and 61.7ｵ of 
CRCs (p＜ .0001).  Thus,  although approximately half 
of normal colonic mucosa possesses SFRP2 methyla-
tion,  its methylation pattern is partial methylation 
(either Region A or B),  observed mainly in Region A.
　 We next analyzed the relationships between levels 
of methylation in both regions of the SFRP2 promoter 
in each subset as a continuous variable.  As shown in 
Fig.  2,  there was a lack of correlation between the 
levels of methylation of Region A and that of Region 
B in N-Cs and N-Ns (p＝－0.1030; p＝0.55,  p＝
0.1801; p＝ .0092,  as well as in APs (p＝0.1515;  
p＝0.13).  However,  there was a signiﬁcant positive 
correlation for methylation at both regions in CRCs 
(p＝0.6000; p＜ .0001).
　 Correlations of SFRP2 methylation with 
clinical and pathological features. Tables 3 
and 4 present the correlations between the methyla-
tion status of SFRP2 and the clinical and pathological 
features in CRCs and APs,  respectively.  In CRCs,  
methylation of the SFRP2 Region B promoter was 
detected more frequently in elderly patients than in 
younger patients (p＝ .03).  We observed no association 
among the frequencies of SFRP2 methylation (partial 
or extensive) and gender,  tumor location,  TNM stag-
ing,  or histology in CRCs.  We next compared the 
SFRP2 methylation status with MSI status.  We 
observed that the SFRP2 Region A promoter region 
was fully (100ｵ) methylated in CRCs showing MSI.
　 Among APs,  methylation of the SFRP2 Region B 
promoter was detected more frequently in tubular 
adenoma with villous architecture than in tubular 
adenoma without such architecture (p＝ .03).  There 
were no signiﬁcant diﬀerences between SFRP2 methy-
lation status and the other clinical factors.  Inter-
estingly,  extensive methylation was rarely observed in 
minor APs but primarily present in advanced APs.
　 We also examined whether or not any associations 
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Fig. 2　 The relationships among methylation levels of Regions A and B in N-Ns,  N-Cs,  APs,  and CRCs.
Table 2　 Frequency of SFRP2 methylation＊
SFRP2 Methylation Status- % (no)
Subset (no)
Non-
methylation
Partial 
methylation
Extensive 
methylation
p-value
Region A methylation
p-value
Region B methylation
p-value
1.0～5.0% ＞5.0% 1.0～5.0% ＞5.0%
N-N (n＝36) 69.4 ( 25 ) 30.6 (11) 　0 ( 0 ) ＜ .0001 25.0 ( 9 )  2.8 ( 1 ) ＜ .0001 2.8 (1) 　0 ( 0 ) ＜ .0001
N-C (n＝208) 56.3 (117) 39.9 (83)  3.9 ( 8 ) 23.6 (49) 17.8 ( 37 ) 4.3 (9)  2.6 ( 4 )
AP  (n＝103) 53.4 ( 55 ) 37.9 (39)  8.7 ( 9 )  2.9 ( 3 ) 35.0 ( 36 ) 5.8 (6) 11.7 ( 12 )
CRC (n＝222) 13.5 ( 30 ) 24.8 (55) 61.7 (137)  4.1 ( 9 ) 79.7 (177) 3.2 (7) 61.3 (136)
＊Methylation of specimens was determined by COBRA.  A specimen was considered positive for methylation if any methylated product was 
detected (i.e.,  a methylation levelｧ1%).  Methylation-positive cases were divided into 2 subsets by their methylation degree: an 1.0～
5.0% methylated group and an over 5.0% methylated group.
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Table 3　Clinicopathological features of CRC patients by SFRP promoter methylation status
Variable
SFRP2 Methylation Status - % (no)
Non-
methylation
Partial 
methylation
Extensive 
methylation
p-value
Region A 
methylation
p-value
Region B 
methylation
p-value
Age ｧ65 (n＝117) 11.1 (13) 20.5 (24) 68.4 ( 80 ) 0.1 　 86.3 (101) 0.28　 70.9 ( 83 ) 0.03　
＜65 (n＝105) 16.2 (17) 29.5 (31) 54.3 ( 57 ) 81.0 ( 85 ) 57.1 ( 60 )
Gender Female (n＝79) 13.9 (11) 22.8 (18) 63.3 ( 50 ) 0.91　 83.5 ( 66 ) 0.97　 65.8 ( 52 ) 0.76　
Male (n＝138) 13.8 (19) 25.4 (35) 60.9 ( 84 ) 83.3 (115) 63.8 ( 88 )
Location Proximal (n＝63) 11.1 ( 7 ) 19.1 (12) 69.8 ( 44 ) 0.3 　 85.7 ( 54 ) 0.41　 73.0 ( 46 ) 0.1 　
Distal (n＝142) 16.2 (23) 25.4 (36) 58.5 ( 83 ) 81.0 (115) 61.3 ( 87 )
T T1 & T2 (n＝35) 14.3 ( 5 ) 20.0 ( 7 ) 65.7 ( 23 ) 0.85　 83.9 ( 29 ) 0.93　 68.6 ( 24 ) 0.6 　
T3 & T4 (n＝169) 14.8 (25) 24.3 (41) 61.0 (103) 82.3 (139) 63.9 (108)
N Node metastasis (－) (n＝89) 11.2 (10) 23.6 (21) 65.2 ( 58 ) 0.45　 86.5 ( 77 ) 0.17　 67.4 ( 60 ) 0.48　
Node metastasis (＋) (n＝115) 17.4 (20) 23.5 (27) 59.1 ( 68 ) 79.1 ( 91 ) 62.6 ( 72 )
M Distance metastasis (－) (n＝164) 12.8 (21) 22.6 (37) 64.6 (106) 0.17　 84.8 (139) 0.07　 67.1 (110) 0.15　
Distance metastasis (＋) (n＝40) 22.5 ( 9 ) 27.5 (11) 50.0 ( 20 ) 72.5 ( 29 ) 55.0 ( 22 )
Stage I &II (n＝91)  9.9 ( 9 ) 28.6 (26) 61.5 ( 56 ) 0.27　 87.9 ( 80 ) 0.14　 63.7 ( 58 ) 0.9 　
III & IV (n＝127) 16.5 (21) 22.1 (28) 61.4 ( 78 ) 80.3 (102) 64.6 ( 82 )
Wel (n＝40) 12.5 ( 5 ) 25.0 (10) 62.5 ( 25 ) 82.5 ( 33 ) 67.5 ( 27 )
Histology Mod (n＝149) 14.1 (21) 25.5 (38) 60.4 ( 90 ) 0.21　 83.2 (124) 0.63　 63.1 ( 94 ) 0.67　
Poor or Muc (n＝15) 26.7 ( 4 ) 　 0 ( 0 ) 73.3 ( 11 ) 73.3 ( 11 ) 73.3 ( 11 )
MSI MSI (n＝15) 　 0 ( 0 ) 33.3 ( 5 ) 66.7 ( 10 ) 0.26　  100 ( 15 ) 0.08　 66.7 ( 10 ) 0.85　
Status Non-MSI (n＝207) 14.5 (30) 24.2 (50) 61.4 (127) 82.6 (171) 64.3 (133)
BRAF/KRAS BRAF Mutant (n＝20) 　 0 ( 0 ) 45.0 ( 9 ) 55.0 ( 11 )  100 ( 20 ) 55.0 ( 11 )
Mutation KRAS Mutant (n＝73)  4.1 ( 3 ) 17.8 (13) 78.1 ( 57 ) 0.0002 93.2 ( 68 ) 0.0008 80.8 ( 59 ) 0.0017
Status Wild-type (n＝129) 20.9 (27) 25.6 (33) 53.5 ( 69 ) 76.0 ( 98 ) 56.6 ( 73 )
T,  invasion by the primary tumor; N,  regional node involvement; M,  distal metastasis; Wel,  well-diﬀerentiated adenocarcinoma;  
Mod,  moderately diﬀerentiated adenocarcinoma; Muc,  mucinous adenocarcinoma.  All p-values were analyzed by the χ2-test.
Table 4　Clinicopathological features of AP patients by SFRP promoter methylation status
Variable
SFRP2 Methylation Status - % (no)
Non-
methylation
Partial 
methylation
Extensive 
methylation
p-value
Region A 
methylation
p-value
Region B 
methylation
p-value
Age ｧ65 (n＝53) 47.2 (25) 43.4 (23)  9.4 (5) 0.42 43.4 (23) 0.23 18.9 (10) 0.7
＜65 (n＝50) 60.0 (30) 32.0 (16)  8.0 (4) 32.0 (16) 16.0 ( 8 )
Gender Female (n＝27) 48.2 (13) 33.3 ( 9 ) 18.5 (5) 0.11 40.7 (11) 0.13 29.6 ( 8 ) 0.05
Male (n＝76) 55.3 (42) 39.5 (30)  5.3 (4) 36.8 (28) 13.2 (10)
Location Proximal (n＝33) 45.5 (15) 45.5 (15)  9.1 (3) 0.52 39.4 (13) 0.83 24.2 ( 8 ) 0.21
Distal (n＝70) 57.1 (40) 34.3 (24)  8.6 (6) 37.1 (26) 14.3 (10)
Size ｧ1cm (n＝82) 53.7 (44) 35.4 (29) 11.0 (9) 0.23 37.8 (31) 0.98 19.5 (16) 0.28
＜1cm (n＝21) 52.4 (11) 47.6 (10) 　0 (0) 38.1 ( 8 )  9.5 ( 2 )
Histology TA (n＝82) 56.1 (46) 36.6 (30)  7.3 (6) 0.44 37.8 (31) 0.98 13.4 (11) 0.03
TA with villous architecture (n＝21) 42.9 ( 9 ) 42.9 ( 9 ) 14.3 (3) 38.1 ( 8 ) 33.3 ( 7 )
KRAS
Mutation
KRAS Mutant (n＝21) 47.6 (10) 47.6 (10)  4.8 (1) 0.52 38.1 ( 8 ) 0.98 19.1 ( 4 ) 0.83
status＊ Wild-type (n＝82) 54.9 (45) 35.4 (29)  9.8 (8) 37.8 (31) 17.1 (14)
TA,  tubular adenoma.  ＊There is no BRAF V600E mutant.
All p-values were analyzed by the χ2-test.
existed between patient age and the degrees of methy-
lation in the discrete regions of the SFRP2 promoter 
in normal mucosa.  However,  no such correlations 
were detected in these analyses (data not shown).
　 Correlation of SFRP2 methylation with 
KRAS mutations in CRCs. We found the BRAF 
V600E mutation in 20 CRCs (9.0ｵ) and in none of the 
APs (0ｵ).  On the other hand,  we found KRAS muta-
tions in 73 CRCs (32.9ｵ) and 21 APs (25.3ｵ).  
Region A was more frequently methylated in CRCs 
with BRAF (100ｵ) or KRAS (93.2ｵ) mutation than in 
CRCs showing the wild type of both genes (76.0ｵ;  
p＝ .0008),  whereas the Region B SFRP2 methylation 
was higher in KRAS mutant CRCs (80.8ｵ) compared 
to BRAF mutant CRCs (55.0ｵ) or both wild-type 
CRCs (56.6ｵ; p＝ .0017).  Therefore,  when we 
compared the complete spectrum of BRAF/KRAS 
mutation with the pattern of SFRP2 methylation,  
extensive methylation was the highest in CRCs with 
KRAS mutation (78.1ｵ) compared to CRCs with 
BRAF mutation (55.0ｵ) or the wild type of both 
genes (53.5ｵ; p＝ .0002; Table 3).  However,  in 
APs,  there were no associations among the SFRP2 
methylation pattern and KRAS mutant APs (Table 4).
Discussion
　 The current study clearly demonstrates for the ﬁrst 
time the biological signiﬁcance of methylation in dis-
crete regions of the SFRP2 promoter in a large cohort 
of specimens obtained from the colon and rectum,  
including neoplasia.  Aberrant methylation in gene 
promoters has been established as a key mechanism 
for the inactivation of tumor suppressor genes in 
human malignancies,  including CRCs [17].  Clinically,  
the identiﬁcation of genes that are prone to abnormal 
methylation and that consequently become downregu-
lated is of critical importance,  since this is consid-
ered to provide a good source of novel biomarkers 
[18,  19].  The family of SFRP genes,  functionally 
acting as Wnt signaling inhibitors,  was recently shown 
to be a common target of promoter hypermethylation 
in numerous tumor entities.  Indeed,  we and others 
have demonstrated that aberrant methylation of the 
SFRP2 promoter region is a potential biomarker with 
which to screen CRCs by analyzing fecal DNA [11,  
12].
　 Generally,  the methylation pattern in CpG islands 
is sometimes considered to be uniformity (either 
entirely methylated or unmethylated).  However,  in the 
SFRP2 promoter region,  our results clearly demon-
strate that methylated alleles do not possess methy-
lated cytosine consistently.  In addition,  by quantifying 
the methylation levels in discrete regions of the 
SFRP2 promoter,  we also illustrated an accumulation 
of aberrant methylation according to the adenoma-
carcinoma sequence.  During this stepwise progres-
sion,  the methylation level of both regions in the 
SFRP2 promoter increased gradually and the existence 
of cytosine methylation expanded widely.  Almost none 
of the nonmalignant specimens,  including normal 
colonic mucosa,  showed extensive methylation in the 
SFRP2 promoter.  More importantly,  extensive 
methylation is a characteristic of a malignant colorec-
tal tumor while partial methylation is a feature of an 
earlier stage of colorectal tumor,  including benign 
polyps.  In this study,  we frequently found N-Ns and 
N-Cs with low density methylation (under 5.0ｵ) in 
Region A (Table 2).  Therefore,  when we considered 
from 1.0ｵ to 5.0ｵ methylation density as methyla-
tion-positive,  approximately 25ｵ of normal colorectal 
mucosa showed low-level (1.0ｵ～5.0ｵ) methylation in 
the SFRP2 Region A promoter.  On the other hand,  
Region B did not show such lower-level (1.0ｵ～
5.0ｵ) methylation in either normal or neoplastic 
lesions.  Thus,  the majority of methylated normal 
colorectal mucosae showed partial methylation (Region 
A),  and there were fewer methylated cells than there 
were in neoplastic lesions with SFRP2 methylation.  It 
is unclear why a quarter of normal colonic mucosae 
had small populations of SFRP2 Region A methylated 
cells.  One explanation for this lower-density methyla-
tion is an association with aging.  Indeed,  methylation 
in estrogen receptor,  hMLH1,  and O6-methylguanine-DNA 
methyltransferase (MGMT) gene promoter observed in 
normal colonic mucosa is associated with aging [20-
22].  However,  by precise analysis of our cohort of 
normal colorectal mucosa,  we could not conﬁrm any 
correlation between the methylation level of CpG sites 
we studied and age.  When we looked into the pattern 
of SFRP2 methylation in colorectal tumors,  we found 
that,  as almost all of the tumors showed little partial 
methylation in Region B,  SFRP2 promoter methyla-
tion would come into existence from Region A to 
Region B consistently.  While we could not ascribe any 
importance to the low level of Region A methylation in 
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N-Cs or N-Ns,  the low level of SFRP2 Region A 
methylation might have the potential to act as a ʻseed 
of methylationʼ,  which is considered to be emerging as 
an important precursor for aberrant methylation [23-
25].
　 It has been suggested that V600E BRAF mutations 
are present in sessile serrated polyps and serrated 
aberrant crypt foci (ACF),  whereas KRAS mutations 
are more highly associated with non-serrated polyps 
and ACFs [26-28].  It is reasonable that,  in this 
study,  we conﬁrmed that there was no BRAF V600E 
mutation in our cohort of APs because of the absence 
of a serrated structure.
　 In this study,  we conﬁrmed that the extensive 
SFRP2 methylation was associated with the KRAS 
mutations in CRCs but not in APs.  It was reported 
that APs with the KRAS mutation showed some degree 
of methylation in multiple loci [29].  Although our 
cohort of APs displayed some degree of SFRP2 
methylation,  most of the methylation pattern of the 
SFRP2 promoter in APs was that of partial methyla-
tion.  We hence conﬁrmed that the frequency of 
extensive SFRP2 methylation was clearly increased in 
CRCs (61.7ｵ) compared to APs (8.7ｵ).  Inter-
estingly,  there was no extensive methylation in APs 
＜1cm in diameter.  This suggests that extensive 
methylation of the SFRP2 promoter might be a critical 
feature of CRC cells and may be necessary to convert 
normal colorectal epithelia to a malignant formation.  
Of particular interest is that we observed for the ﬁrst 
time a gradual increase in the SFRP2 methylation 
density in the 2 promoter regions from the normal-
adenoma-carcinoma sequence.  Although the detailed 
mechanisms underlying hypermethylation are still 
unclear,  we can present a new hypothesis to explain 
tumorigenesis according to the adenoma-carcinoma 
sequence when we combine the results obtained from 
this study into the data we previously reported.  Fig.  
3 shows the schema of our modiﬁed adenoma-carci-
noma sequence [8,  14,  15].  Our hypothesis is as 
follows:
1) ﬁrst,  in normal colorectal epithelium,  the ʻseed of 
methylationʼ comes into existence;
2) next,  alteration of the RAS-RAF pathway (includ-
ing BRAF or KRAS mutations) initiates the direction 
and characteristics of neoplasia (this alteration may 
occur in small adenomas);
3) ﬁnally,  aberrant methylation spreads to certain 
directions according to the mutation spectra of 
BRAF/KRAS (i.e.,  if a neoplasia gains the BRAF 
V600E mutation,  the neoplasia would transform into 
polyps with a serrated structure and accumulate dense 
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Fig. 3　 Epigenetic model of colorectal tumorigenesis.  Tumorigenesis proceeds through a series of epigenetic alterations.  First,  in nor-
mal colorectal epithelium,  a ʻseed of methylationʼ comes into existence.  Second,  in small adenoma,  alteration of the RAS-RAF pathway 
(including BRAF or KRAS mutations) initiates the direction and characteristics of neoplasia.  Third,  aberrant methylation spreads in certain 
directions according to the mutation spectra of BRAF/KRAS (i.e.,  if a small polyp gains the BRAF V600E mutation,  the polyp would 
transform into polyps with a serrated structure and accumulate dense methylation in the hMLH1/p16 promoter,  and consequently become 
sporadic MSI cancer [15,  25].  If a small adenoma gains KRAS mutations,  the adenoma would transform into tubular adenoma with villous 
architecture and accumulate dense methylation in the SFRP2/MGMT promoter,  consequently becoming non-MSI cancer [8,  14]).
methylation in the hMLH1/p16 promoter,  and conse-
quently become sporadic MSI cancer [15,  25].  If a 
neoplasia gains KRAS mutations,  the neoplasia would 
transform into tubular adenoma with villous architec-
ture and accumulate dense methylation in the SFRP2/
MGMT promoter,  consequently becoming non-MSI 
cancer [8,  14]).
　 In conclusion,  the current data clearly suggested 
that the extensive methylation in the discrete SFRP2 
promoter regions associate with a malignant form of 
colorectal neoplasia,  while partial methylation in those 
regions,  commonly detected in the earlier stage of 
colorectal neoplasia and also in normal colonic mucosa,  
may represent a transitional stage that may progress 
to the advanced stage during colorectal tumorigenesis.  
These ﬁndings are pivotal in this context,  as they 
form a basis on which aberrant methylation of SFRP2 
may be exploited as a potential diagnostic screening 
marker for subjects at risk for developing colorectal 
neoplasia as well as for patients with CRC.
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